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Abstract 
Philanthotoxin-433 (PhTX-433) is an active component of the venom from the Egyptian digger 
wasp, Philanthus triangulum. PhTX-433 non-selectively inhibits several excitatory ligand-
gated ion channels, and we recently showed that its synthetic analogue, PhTX-343, exhibits 
strong selectivity for neuronal over muscle-type nicotinic acetylcholine receptors (nAChRs). 
Here we examined the action of seventeen analogues of PhTX-343 against ganglionic (α3β4) 
and brain (α4β2) nAChRs expressed in Xenopus oocytes by using two-electrode voltage-clamp 
at 100 mV. IC50 values for PhTX-343 inhibition of α3β4 and α4β2 receptors were 7.7 nM and 
80 nM, respectively. All of the studied analogues had significantly higher potency at α3β4 
nAChRs with IC50 values as low as 0.16 nM and with up to a 91-fold selectivity for α3β4 over 
α4β2 receptors. We conclude that PhTX-343 analogues displaying both a saturated ring and an 
aromatic moiety in the hydrophobic headgroup of the molecule demonstrate exceptional 
potency and selectivity for α3β4 nAChRs.  
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Introduction 
A constituent of the venom of the Egyptian digger wasp, Philanthus triangulum, is the 
polyamine-containing toxin, known as philanthotoxin-433 (PhTX-433; Fig. 1), which enables 
paralysis of its insect prey through inhibition of ionotropic glutamate receptors (iGluRs) and 
nicotinic acetylcholine receptors (nAChRs).1, 2 The structure of PhTX-433 consists of a central 
tyrosine residue amide-linked to a thermospermine moiety on one side and to an n-butanoyl 
chain on the other (Fig. 1). The resulting molecule thus has a relatively bulky and hydrophobic 
‘headgroup’ and a positively charged (+3) ‘tail’ at physiological pH. Although the wasp has 
evolved to produce toxins targeting iGluRs and nAChRs in insects, PhTX-433 and its 
structurally very similar synthetic analogue, PhTX-343 (1; Fig. 1), are also potent inhibitors of 
vertebrate ionotropic receptors. These latter interactions have been well characterized at 
mammalian iGluRs, including the N-methyl-D-aspartate (NMDA), kainate and α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors;3, 4 as well as for vertebrate 
muscle-type5, 6 and neuronal-type7, 8 nAChRs. In our recent study on neuronal nAChRs, it was 
found that PhTX-343 is a very potent inhibitor of heteromeric receptors with selectivity for the 
ganglionic 34 subtype.7 
 
 
Figure 1. Structures of naturally occurring PhTX-433 and its synthetic analogue PhTX-343 
(1), used as a template for the analogues studied in the present work. 
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Inhibition of both nAChRs and iGluRs by PhTX-343 has been shown to be use- and voltage-
dependent (with increased inhibition occurring at more negative membrane potentials), and 
this has led to the hypothesis that open-channel blocking is the dominant mode of action, with 
the polyamine tail penetrating deep into the channel pore and interacting with polar amino 
acids, while the headgroup interacts with rings of hydrophobic amino acids at a more 
extracellular location in the pore.9, 10 Further evidence for this mechanism resulted from 
experiments showing that AMPA receptors lacking the GluA2 subunit are highly sensitive to 
PhTX-343, whereas those containing GluA2 are almost insensitive.11 This can be explained by 
RNA editing of GluA2, resulting in a single amino acid substitution at the so-called “Q/R site” 
that forms the selectivity filter within the pore.9 Likewise, mutations in the outer pore of 
nAChR affect the affinity for PhTX-343.7 
Studies into the importance of the amine functionalities resulted in the first breakthrough in 
receptor selectivity. Thus, the analogue PhTX-12, in which the two secondary amines in PhTX-
343 were replaced with methylene groups, had an expected reduced potency at AMPA 
receptors and NMDA receptors, but unexpectedly inhibition of muscle-type nAChRs was 
significantly increased.4 However, the latter was accompanied by a change in the mode of 
action, since inhibition remained strong at positive membrane potentials and voltage 
dependence was weak.6, 10 In another study it was found that exchange of the tyrosine moiety 
in PhTX-343 for a cyclohexylalanine unit generated a toxin with considerably enhanced 
inhibitory activity at muscle-type nAChR.12 
In the present work, we investigated PhTX-343 (1) and its headgroup-modified analogues (i.e., 
compounds 2-18; Table 1) with single or combined structural alterations in the n-butanoyl, 
tyrosine and polyamine moieties for their inhibitory actions against the α4β2 and α3β4 subtypes 
of neuronal nAChRs. We aimed to develop analogues capable of distinguishing between 
neuronal heteromeric nAChR subtypes. Recently, there has been considerable interest in 
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compounds that selectively inhibit the α3β4 subtype of nAChRs as a potential treatment for 
nicotine addiction due to their significant expression in the medial habenula that modulates the 
mesolimbic dopaminergic response to nicotine.13 Hence, potent and selective α3β4 nAChR 
antagonists have the potential to aid smoking cessation.14, 15 
 
Results  
Synthesis of PhTX-343 analogues 
The novel PhTX analogues 5, 6, 10, 11, and 13-17 were prepared by using a solid-phase 
synthesis (SPS) protocol similar to that reported previously for the known analogues 9, 12, and 
18 displaying a cyclohexylalanine (Cha) residue.16 In brief, a large batch of trityl chloride 
polystyrene resin was loaded with an equimolar amount of mono-[2-
(trimethylsilyl)ethyloxycarbonyl] (Teoc)-protected di-Boc-spermine (Scheme 1) in order to 
avoid the issue with cross-linking of the trityl linker moities observed when employing di-Boc-
spermine (i.e., H2N(CH2)3NHBoc(CH2)4NHBoc(CH2)3NH2).
17 Next, unreacted trityl groups 
were capped with methanol in the presence of base (i.e., iPr2EtN in CH2Cl2), and subsequent 
removal of the Teoc N-protecting group by treatment with tetrabutylammonium fluoride 
afforded resin 19. The prepared large batch of resin 19 was divided into several reactors to 
complete the last steps in the SPS of the individual analogues in parallel. This comprised 
acylation with the appropriate fluoren-9-yl-oxycarbonyl (Fmoc)-protected amino acid building 
blocks (i.e., Fmoc-Tyr(tBu)-OH or Fmoc-Cha-OH) by standard diisopropylcarbodiimide 
(DIC)-1-hydroxybenzotriazol (HOBt) amide coupling to provide resins 20a and 20b, which 
then were Fmoc-deprotected and acylated with the selected different carboxylic acids under 
standard DIC-HOBt conditions. Subsequent cleavage (from resins 21a-21i) and purification 
furnished PhTX analogues 5, 6, 10, 11, and 13-17 in 16% to 73% yield. 
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Scheme 1. Solid-phase synthesis of novel PhTX analogues.a  
 
a Reagents: (i) iPr2EtN (3 equiv), CH2Cl2, 3 days at room temperature; (ii) 
iPr2EtNMeOHCH2Cl2 (5:15:80, 2 × 15 min); (iii) Bu4NF (4 equiv), DMF, 50 ºC, 1 h, then 
1 h at room temperature; (iv) Fmoc-Cha-OH or Fmoc-Tyr(tBu)-OH (3 equiv), DIC (3 equiv), 
HOBt (3 equiv), DMF, pre-activation for 20 min then 20 h after addition to resin; (v) 20% 
piperidine-DMF, 2 × 10 min; (vi) R'-COOH (5 equiv), DIC (5 equiv), HOBt (5 equiv), DMF, 
16 h; (vii) 50% TFA-CH2Cl2, 2 h. 
 
Our reference compound, PhTX-343 (1), had IC50 values of 7.7 nM and 80 nM at α3β4 and 
α4β2 receptors, respectively, thus displaying a 10-fold selectivity for the α3β4 subtype over 
the α4β2 subtype (Fig. 2; Table 1). Of the seventeen analogues (i.e., 2-18) only one compound 
(i.e., 9) was a less potent antagonist of the α4β2 subtype, while all analogues were more 
efficient antagonists of the α3β4 subtype (Fig. 3A-B). With respect to high selectivity for α3β4 
over α4β2 receptors, two compounds (i.e., 5 and 16) were identified as being particularly 
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promising (Fig. 3C). The results obtained for each subset of analogues, characterized by the 
number and type of structural modifications, are presented in more detail below.   
 
Table 1. IC50 values for inhibition of α3β4 or α4β2 receptors by compounds 1-18. 
 
 α3β4 
 
α4β2 
 
 
Compound IC50, nM (95% CI) RP IC50, nM (95% CI) RP Sel 
1 
 
7.65 (6.31-9.28) 1.0 80.2 (48.5-132) 1.0 10.5 
2 
 
0.93 (0.61-1.42) 8.2 27.8 (19.3-40.0) 2.9 29.9 
3 
 
1.74 (1.17-2.60) 4.4 20.8 (14.5-29.9) 3.9 12.0 
4 
 
2.62 (1.55-4.44) 2.9 2.58 (0.98-6.75) 31.1 1.0 
5 
 
0.46 (0.35-0.61) 16.6 36.6 (28.6-46.8) 2.2 79.6 
6 
 
0.57 (0.44-0.74) 13.4 22.5 (17.3-29.3) 3.6 39.5 
7 
 
0.92 (0.69-1.23) 8.3 44.3 (36.3-54.2) 1.8 48.2 
8 
 
1.44 (0.99-2.10) 5.3 47.4 (40.0-56.1) 1.7 32.9 
9 
 
2.63 (2.12-3.28) 2.9 112 (80.4-155) 0.7 42.6 
7 
 
10 
 
1.07 (0.80-1.45) 7.1 20.8 (9.12-47.4) 3.9 19.4 
11 
 
0.65 (0.40-1.06) 11.8 5.43 (2.99-9.86) 14.8 8.4 
12 
 
2.19 (1.55-3.11) 3.5 31.4 (20.3-48.4) 2.6 14.3 
13 
 
0.55 (0.44-0.70) 13.9 28.2 (19.1-41.5) 2.8 51.3 
14 
 
0.95 (0.64-1.39) 8.1 25.6 (16.8-39.2) 3.1 26.9 
15 
 
0.37 (0.22-0.64) 20.7 21.4 (14.2-32.3) 3.7 57.8 
16 
 
0.16 (0.11-0.23) 47.8 14.6 (11.0-19.4) 5.5 91.3 
17 
 
0.35 (0.28-0.43) 21.9 12.1 (8.47-17.4) 6.6 34.6 
18 
 
2.83 (1.51-5.30) 2.7 25.8 (17.4-38.4) 3.1 9.1 
RP = relative potency as compared to that of 1 for the receptor subtype; Sel = selectivity of 
the compound for α3β4 over α4β2; 95% CI = 95% confidence interval; n = 4-20 oocytes. 
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Potency of analogues with substitution of tyrosine only 
Three of the investigated analogues (2-4) contained alternative central amino acids instead of 
tyrosine (Tyr), thereby conferring increased hydrophobicity to the side chain (Table 1). 
Compounds 2 and 3 with a phenylalanine (Phe) moiety or its homologue (hPhe) instead of Tyr 
exhibited increased potency at both nAChR subtypes, which was more pronounced for α3β4, 
thus leading to increased selectivities of 30-fold and 12-fold, respectively. Compound 4, having 
a cyclohexylalanine (Cha) residue in place of Tyr, proved more potent than 1 at both nAChR 
subtypes, but noticeably all selectivity for α3β4 over α4β2 was abrogated (Fig. 2; Table 1). 
Interestingly, analogue 4 was the only compound tested in this study that showed this non-
selective behaviour, while it was the most potent inhibitor of α4β2 receptors (Fig. 2B). 
 
Potency of analogues with alternative N-acyl moieties 
In analogues 5-6, the N-acyl moieties comprise cyclohexanoyl or cyclopentanoyl instead of the 
original N-butanoyl group, which confer increased bulk and hydrophobicity to the headgroup 
(Table 1). Analogues 5 and 6 showed a strong increase in potency at α3β4 receptors, but less 
so at α4β2 receptors, and hence selectivity for α3β4 was increased up to 80-fold for compound 
5.  
 
Potency of analogues with modifications in the polyamine tail moiety 
Analogues 7 and 8 contain a cyclopropane ring in the centre of the polyamine moiety in a trans 
or cis conformation, respectively (Table 1). Both compounds exhibited moderately increased 
potency at α3β4 receptors as compared to that of 1, whereas they only displayed weakly 
improved inhibition of α4β2 receptors. This gave rise to increased selectivity of 7 and 8 for 
α3β4 receptors to 48-fold and 33-fold, respectively. 
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Figure 2. Inhibition of nAChR responses by PhTX-343 analogues. A-B: Two-electrode 
voltage clamp (TEVC) current responses of α3β4 (A) or α4β2 (B) nAChRs to 100 μM or 10 
μM ACh respectively, in the absence and co-applied with compounds 1, 4 or 16. C-D: 
Concentration-inhibition curves for inhibition of α3β4 (C) or α4β2 (D) nAChRs by compounds 
1, 4 or 16. Data points are represented as mean ± SEM (n = 3-9), and curves were obtained via 
fitting to Eq. 1 (see experimental section on data analysis). IC50 values are given in Table 1. 
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Figure 3. Summary of potency and selectivity of inhibition of α3β4 and α4β2 nAChR subtypes 
by compounds 1-18. A: IC50 values for inhibition of α3β4 (blue bars) or α4β2 (red bars). Error 
bars indicate 95% CI. B: Relative potency as compared to that of 1 (i.e., PhTX-343) for each 
nAChR subtype (α3β4 - blue bars; α4β2 - red bars). C: Selectivity for the α3β4 subtype. 
 
Potency of analogues with a combination of two headgroup modifications 
This set of ten compounds all contain a Tyr  Cha substitution. The effect of this change alone 
can be seen in the inhibitory profile of analogue 4, for which no selectivity for α3β4 over α4β2 
was found. Six of the compounds (i.e., 9-14), containing small to large saturated ring systems 
instead of the n-butanoyl moiety (Table 1), showed minor to moderately increased potency at 
α3β4 receptors, while displaying reduced to moderately increased potency at α4β2 receptors, 
except for analogue 11 that was a 15-fold more potent inhibitor than 1 at the latter receptor. 
Selectivity for α3β4 was variable within this series of six compounds with 11 having slightly 
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reduced selectivity as compared to that of 1, while 9 and 13 proved to be considerably more 
selective (43-fold and 51-fold, respectively) than the original lead compound (i.e., 1). 
The remaining four compounds in this subclass (i.e., 15-18) all have aromatic N-acyl 
substituents (Table 1). Except for 18, containing an extended and rigid biphenyl group, the 
introduction of aromatic moieties resulted in very strongly increased inhibitory potency (as 
compared to that of 1) at α3β4 receptors. By contrast, only weak to moderate enhancement of 
potency at α4β2 was observed for these analogues, resulting in a highly improved selectivity 
for α3β4. In fact, compound 16, carrying a naphthoyl group proved to be the most potent and 
selective among all the analogues tested in the present study, as it was 48-fold more potent than 
1 at α3β4 (i.e., with an IC50 = 0.16 nM) combined with a selectivity of 91-fold in favour of 
α3β4 (Fig. 2 and 3).  
 
Discussion and Conclusion 
In the present work it was demonstrated that analogues of PhTX-343 (1) can be designed to 
exhibit extremely high antagonistic potency at nAChR receptors, and in particular at the α3β4 
subtype. The most potent analogue was 16, containing an N-naphthoyl-Cha headgroup and a 
spermine polyamine tail, with an IC50 of 0.16 nM. This is certainly the most potent known 
PhTX-343-derived antagonist of nAChR, and to our knowledge it is the most potent nAChR 
antagonist reported to date. Additionally, compound 16 has high selectivity for α3β4 over α4β2, 
and based on our recent observations that PhTX-343 selectively inhibits 4-containing 
nAChRs (especially α3β4) over all of the other major nAChR subtypes (i.e., α4β2, α3β2, α7 
and α1β1γδ)7 it is expected that this will be the case also for 16. Many of the compounds 
described in the present work also compare favourably to a recently identified synthetic α-
conotoxin, TP-2212-59, that selectively targets α3β4 nAChRs with a low nanomolar IC50 value 
(2.3 nM).18 However, a direct comparison between compounds belonging to these two distinct 
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classes of antagonists are not straightforward due to their different binding sites and mode of 
action.  
The proposed binding site for PhTX-343 and its analogues, having similar highly charged 
polyamine tail regions, is located within the nAChR pore, whereby the polyamine moiety 
inserts deeply into the pore in order to interact with the threonine and serine rings beyond the 
equatorial leucine gate, while the bulky and hydrophobic headgroup interacts with hydrophobic 
residues of the valine and leucine rings that line the outer part of the pore.10 
Compound 16 possesses modifications in both the N-acyl and the central amino acid residue, 
and it may thus be considered  to be a further modification of PhTX(Cha)-343 (4), which 
previously was identified as an antagonist of human muscle nAChRs in TE671 cells, where it 
proved 277-fold more potent than 1 at VH = –100 mV.12 Nevertheless, in the present study, by 
using the same holding potential, only a 2.9-fold increase in relative potency of 4 (versus that 
of 1) at α3β4 was found, most likely arising from the fact that 1 is much more potent (317-fold) 
at α3β4 than at the α1β1γδ subtype.7  
Interestingly, the four most potent analogues at α3β4 receptors, having IC50 values < 0.5 nM 
(i.e., 5, 15, 16 and 17), all shared the structural characteristic of a more bulky and hydrophobic 
headgroup, consisting of a saturated aliphatic ring and an aromatic group. A putative 
explanation for this relates to our understanding of why PhTX-343 is selective for 4-
containing nAChRs.7 Earlier it was proposed that the α3β4 selectivity arises from the presence 
of a phenylalanine residue (F275; in the rat receptor) uniquely found at the valine ring in 4 
subunits.7 This Phe promotes aromatic stacking interactions and greatly increases affinity of 
appropriately substituted ligands, which also may provide a rationale as to why 5, 6, 15, 16 and 
17 display enhanced selectivity for α3β4 over α4β2. Based on this hypothesis, compound 18 
might also be expected to be a highly potent and selective inhibitor of α3β4 receptors, however, 
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its aromatic moiety is quite extended and rigid, which may restrict access to its binding position 
due to steric hindrance. 
Other highly potent compounds comprise 11, 13 and 14 that have a Tyr  Cha substitution 
and a bulky saturated hydrophobic aliphatic ring structure instead of the linear n-butanoyl 
moiety. This increases headgroup hydrophobicity considerably, and it is beneficial for 
interaction with valine and leucine residues in the outer pore regions of both nAChR subtypes. 
Furthermore, compounds 2 and 7 also had sub-nanomolar IC50 values, and 2 was previously 
found to have increased potency at Torpedo electric organ nAChRs through testing in a 
[3H]H12-HTX binding assay,
19 presumably because of an increased headgroup hydrophobicity 
induced by the Tyr  Phe substitution resulting in the absence of a hydroxyl group. Compound 
7 has a cyclopropane functionality inserted into the centre of the spermine moiety, and previous 
modelling studies indicate that internal hydrogen bonding between the amine closest to the 
headgroup and the amide oxygens will position the cyclopropane unit so that it contributes to 
the bulkiness of the headgroup.10, 20  
At α4β2 receptors analogue 4 was the most potent antagonist, whereas it was one of the least 
potent compounds at α3β4 receptors. This most likely arises from the absence of an aromatic 
moiety in the headgroup, providing improved hydrophobic interactions with the valine and 
leucine residues in the outer pore region of α4β2 than any of the other compounds. The second 
most potent compound (i.e., 11) at α4β2 also lacked an aromatic group, however, other non-
aromatic compounds had lower potency, presumably due to lack of optimal shape and/or size 
restrictions. 
In summary, PhTX-343 analogues displaying both a saturated ring structure and an aromatic 
moiety in the headgroup demonstrate extreme potency and selectivity for the α3β4 nAChR 
subtype, and it is hypothesised that this arises from the unique presence of a Phe residue in the 
outer pore region of this receptor subtype. The most selective compounds identified may have 
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potential as smoking cessation therapies and find application as useful probes in the study of 
nicotine addiction. 
 
Experimental Section  
Materials. Starting materials (amino acid building blocks, trityl chloride polystyrene resin, 
and reagents) and solvents were obtained from commercial suppliers (Iris Biotech, Sigma-
Aldrich, VWR, Labscan and CHEMsolute) and used as received. CH2Cl2 was distilled from 
P2O5 and stored over 4 Å molecular sieves.  
Acetylcholine (ACh) was from Sigma. PhTX-343 (1) was synthesized as described in 
Wellendorph et al.21 Some analogues have been synthesized previously: Compounds 2 and 3;22 
compound 4,12 compounds 7 and 8,20 as well as compounds 9, 12, and 18.16 cDNA clones of 
rat neuronal nAChR subunits (α3, α4, β2 and β4) were from the Salk Institute for Biological 
Studies (Professor Stephen Heinemann). Plasmids were linearized and cRNA transcribed using 
an mMessage mMachine kit (Ambion). 
General Methods for Purification and Compound Characterization. Solid-phase 
conversions were carried out in Teflon filter vessels on a Scansys PLS 4 × 6 Organic 
Synthesizer equipped with a heating block. Water used during analytical and preparative HPLC 
was filtered through a 0.22 μm membrane filter. Preparative HPLC was performed by using a 
Luna C18(2) column (250 mm × 21.2 mm; particle size: 5 µm) on an Agilent 1100 LC system 
consisting of two preparative pump units and equipped with a multiple-wavelength UV 
detector. Linear gradients for elution were composed by mixing solvent A (MeCN–H2O–TFA 
5:95:0.1) and B (MeCN–H2O–TFA 95:5:0.1) at a flow rate of 20 mL/min; injection volumes 
were 300-900 μL. Analytical HPLC was performed on a Shimadzu system comprising an SCL-
10A VP controller, an SIL-10AD VP autosampler, an LC-10AT VP pump, an SPD-M10A VP 
diode array detector, and a CTO-10AC VP column oven, using a Phenomenex Luna C18(2) 
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column (150  4.6 mm; particle size: 3 µm). The HPLC system was controlled by Class VP 6 
software; elution with a flow of 0.8 mL/minute; injection volumes were 5-10 μL of ~1 mg/mL 
solutions, and separations were performed at 40 °C. The same eluents as for preparative HPLC 
(i.e., A = MeCN–H2O–TFA 5:95:0.1 and B = MeCN–H2O–TFA 95:5:0.1) were used. The 
purities of target compounds 5, 6, 10, 11 and 13-17 (as determined from UV absorption 
integration at  = 210 nm or 220 nm) were at least 95%. 1H and 13C nuclear magnetic resonance 
(NMR) spectra were acquired on a 600 MHz Bruker Avance III HD spectrometer equipped 
with a cryogenically cooled 5 mm dual probe optimzed for 1H and 13C. Samples were dissolved 
in methanol-d4 (Cambridge Isotope Laboratories), and was then analyzed at 300 K using the 
residual solvent peak internal standard (i.e., C = 49.00 ppm and H = 3.31 ppm). Coupling 
constants (J values) are given in hertz (Hz), and multiplicities of 1H NMR signals are reported 
as follows: singlet (s), doublet (d), doublet of doublets (dd), triplet (t), pentet (p), multiplet (m); 
broadened (br). Additional peaks due to the presence of rotamers or presence of chiral centers 
are designated by an asterisk (*); two close signals with almost the same chemical shift value 
is indicated by two asterisks (**). Numbering of carbon atoms: polyamine is numbered 1, 2, 3 
etc starting from the amide terminus; amino acid moiety is numbered , β,  etc; the N-acyl 
moiety is numbered 1', 2', 3' etc. High-resolution MALDI-TOF spectra were obtained on a 
Bruker SolariX XR in MALDI mode giving (m/z): [M + H]+ with M below 2 ppm.  
Synthesis of philanthotoxin analogues. The novel PhTX analogues 5, 6, 10, 11, and 13-17 
were prepared in a similar manner to that reported previously.16 In brief, trityl chloride 
polystyrene resin (1.66 g, 2.2 mmol/g) in a syringe (20 mL, fitted with a polypropylene filter 
and a Teflon valve), was swelled in dry CH2Cl2 and then treated with 10% iPr2EtNCH2Cl2 
(10 mL) for 5 min, and finally washed with CH2Cl2 (2 × 10 mL; each for 5 min). Then 
H2N(CH2)3-NBoc(CH2)4NBoc(CH2)3NHTeoc
21 (2.00 g, 3.65 mmol) and iPr2EtN (1.9 mL, 3 × 
3.65 mmol) in CH2Cl2 (25 mL) was added to the resin in a round-bottomed flask (50 mL). After 
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gentle stirring for 3 days, the resin was transferred to a syringe (20 mL), washed with CH2Cl2 
(2 × 15 mL, each for 5 min), and capped with iPr2EtNMeOHCH2Cl2 (5:15:80, 2 × 15 mL, 
each for 15 min). Upon draining, the resin was washed with CH2Cl2, DMF, and CH2Cl2 (each 
3 ×), and then transferred to a round-bottomed flask (100 mL), in which Teoc deprotection was 
performed with Bu4NF (3 equiv) in dry DMF (50 mL) for 1 h at 50 C followed by 1 h at room 
temperature. The resin was transferred to a syringe followed by draining and washing with 
DMF, MeOH, DMF, and CH2Cl2 (each 3 ×) and finally dried for 16 h to yield resin-bound 
spermine (2.93 g, 1.2 mmol/g). Portions of the resin (0.120 g, 0.15 mmol) were placed in 
Teflon filter vessels, and were then preswollen in dry DMF (5 mL). A mixture of Fmoc-Cha-
OH (3 equiv) or Fmoc-Tyr(tBu)-OH (3 equiv), DIC (3 equiv), and HOBt (3 equiv) in dry DMF 
(3 mL/reactor) was stirred for 20 min, filtered, and added (ca. 3 mL) to each of the resins in the 
filter vessels, which were shaken for 20 h, drained and washed with DMF, MeOH, DMF, and 
CH2Cl2 (each 3 ×), and then Fmoc-deprotected with 20% piperidine–DMF (3 mL, 2 × 10 min). 
Following wash with DMF (5 ×), a preincubated  (for 15 min) mixture of the appropriate 
carboxylic acid (5 equiv), HOBt (5 equiv), and DIC (5 equiv) in dry DMF (3 mL) was added 
to the respective reactors, which then were shaken at room temperature for 16 h. The resins 
were then drained and washed with DMF, MeOH, DMF, and CH2Cl2 (each 3 ×). Cleavage of 
the products from the resin was performed with 50% TFACH2Cl2 (5 mL for 2 h). The resins 
were further eluted with CH2Cl2 and MeOH (each 2 × 5 mL); the total eluates from each reactor 
were co-evaporated with tolueneMeOH 1:1 (3 × 10 mL). The resulting crude products were 
dried overnight, and then purified by preparative HPLC (by using a linear gradient rising from 
5% B to 100% B during 20 min) to give PhTX analogues 5, 6, 10, 11, and 13-17 as the tris(TFA) 
salts. Compounds 10 and 11 required rechromatography (using a linear gradient from 5% B to 
60% B during 20 min) to obtain samples with sufficient purity. 
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PhTX analogue 5 (5): Yield: 58 mg (47%); tR = 18.56 min. HRMS: calcd for C26H45N5O3 
[M + H]+ 476.3601, found 476.3600. 1H NMR (600 MHz, CD3OD): δ 7.05 (2H, d, J = 8.5 Hz, 
H-b/H-b'), 6.71 (2H, d, J = 8.5 Hz, H-c/H-c'), 4.38 (1H, t, J = 7.8 Hz, H-), 3.29-3.17 (2H, br 
m, H-1), 3.16-3.13 (2H, m -CH2-NH-) and 3.11-3.04 (4H, m, -CH2-NH-), 3.02-2.94 (3H, m, 
HA-β and -CH2-NH-), 2.91-2.82 (3H, br m, HB-β and -CH2-NH-), 2.22 (1H, m, H-2'), 2.09 (2H, 
m, H-9), 1.84-1.72 (9H, br m, H-2, H-5, H-6, 3 × cHex-Heq), 1.70-1.65 (2H, cHex-Heq), 1.40-
1.16 (5H, br m, cHex-Hax). 
13C NMR (150 MHz, CD3OD): δ 179.2, 175.2, 157.4, 131.3 (2C), 
128.9, 116.3 (2C), 56.9, 48.3, 48.2, 46.2, 45.9 (2C), 37.9, 37.8, 36.7, 30.8, 30.3, 27.4, 26.9, 
26.8, 26.6, 25.4, 24.3, 24.2. 
PhTX analogue 6 (6): Yield: 88 mg (73%); tR = 16.98 min. HRMS: calcd for C25H43N5O3 
[M + H]+ 462.3444, found 462.3444. 1H NMR (600 MHz, CD3OD): δ 7.05 (2H, d, J = 8.5 Hz, 
H-b/H-b'), 6.72 (2H, d, J = 8.5 Hz, H-c/H-c'), 4.37 (1H, t, J = 7.7 Hz, H-), 3.26 and 3.20 (each 
1H, m, H-1), 3.16-3.12 (2H, m -CH2-NH-) and 3.10-3.04 (4H, m, -CH2-NH-), 3.01-2.95 (3H, 
m, HA-β and -CH2-NH-), 2.91-2.82 (3H, br m, HB-β and -CH2-NH-), 2.67 (1H, m, H-2'), 2.09 
(2H, m, H-9), 1.85-1.75 (8H, br m, H-2, H-5, H-6, and 2 × cPent-H), 1.71-1.63 (3H, br m, 
cPent-H), 1.62-1.50 (3H, br m, cPent-H). 13C NMR (150 MHz, CD3OD): δ 179.3, 175.2, 157.4, 
131.3 (2C), 128.9, 116.3 (2C), 57.0, 48.3, 48.2, 46.2, 46.0, 45.9, 38.0, 37.8, 36.7, 31.8, 31.0, 
27.4, 27.0, 26.9, 25.4, 24.3, 24.2.  
PhTX analogue 10 (10): Yield: 23 mg (20%) and a fraction of almost pure 10 (25 mg); tR = 
15.45 min. HRMS: calcd for C24H47N5O [M + H]
+ 438.3803, found 438.3800. 1H NMR (600 
MHz, CD3OD): δ 4.23 (1H, br t, J = 7.7 Hz, H-), 3.35 and 3.27 (each 1H, m, H-1), 3.22 (1H, 
p, J = 8.5 Hz, H-2'), 3.14 (2H, m, -CH2-NH-), 3.10-2.99 (8H, br m, 4 × -CH2-NH-), 2.26 (1H, 
m, cBut-H), 2.22-2.16 (2H, br m, cBut-H), 2.15-2.06 (3H, br m, H-9, cBut-H), 2.00 (1H, m, 
cBut-H), 1.90-1.83 (3H, H-2 and cBut-H), 1.80 (4H, m, H-5 and H-6), 1.78-1.70 (4H, br m, 
cHex-Heq), 1.67 (1H, m, cHex-Heq), 1.57 (2H, br t, J = 7.4 Hz, H-β), 1.35 (1H, m, H-), 1.30-
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1.15 (3H, br m, cHex-Hax), 1.01-0.79 (2H, br m, cHex-Hax). 
13C NMR (150 MHz, CD3OD): δ 
178.1, 176.8, 53.1, 48.3, 48.2, 46.2, 45.9, 40.4, 40.2, 37.8, 36.7, 35.5, 34.8, 33.3, 27.6, 27.5, 
27.4, 27.2, 26.5, 25.7, 25.4, 24.3 (2C), 19.1.  
PhTX analogue 11 (11): Yield: 19 mg (16%) and a fraction of almost pure 11 (21 mg); tR = 
16.91 min. HRMS: calcd for C25H490N5O2 [M + H]
+ 452.3959, found 452.3958. 1H NMR (600 
MHz, CD3OD): δ 4.24 (1H, dd, J = 9.3 and 6.0 Hz, H-), 3.35 and 3.28 (each 1H, m, H-1), 
3.13 (2H, br t, J = 7.8 Hz, -CH2-NH-), 3.10-2.99 (8H, br m, 4 × -CH2-NH-), 2.74 (1H, p, J = 
7.9 Hz, H-2'), 2.08 (2H, m, H-9), 1.94-1.78 (8H, H-2, H-5, H-6 and 2 × cPent-H), 1.77-1.65 
(9H, 4 × cPent-H and 5 × cHex-Heq), 1.64-1.54 (4H, 2 × cPent-H and H-β), 1.37 (1H, m, H-), 
1.32-1.15 (3H, br m, cHex-Hax), 1.02-0.80 (2H, br m, cHex-Hax). 
13C NMR (150 MHz, 
CD3OD): δ 179.7, 176.8, 53.2, 48.3, 48.2, 46.2, 46.0, 45.9, 40.2, 37.8, 36.7, 35.5, 34.8, 33.3, 
32.0, 31.0, 27.6, 27.5, 27.4, 27.2, 27.1, 27.0, 25.4, 24.3 (2C). 
PhTX analogue 13 (13): Yield: 50 mg (40%); tR = 18.67 min. HRMS: calcd for C27H54N5O2 
[M + H]+ 480.4272, found 480.4272. 1H NMR (600 MHz, CD3OD): δ 4.21 (1H, dd, J = 9.7 
and 5.6 Hz, H-), 3.35 and 3.27 (each 1H, m, H-1), 3.13 (2H, br t,  J = 7.7 Hz, -CH2-NH-), 
3.10-2.99 (8H, br m, 4 × -CH2-NH-), 2.45 (1H, m, H-2'), 2.09 (2H, m, H-9), 1.89-1.71 (14H, 
m, H-2, H-5, H-6, 4 × cHex-Heq, 4 × cHep-H), 1.70-1.46 (11H, cHex Heq, 8 × cHep-H, H-β), 
1.37 (1H, m, H-), 1.34-1.15 (3H, br m, cHex-Hax), 1.02-0.87 (2H, br m, cHex-Hax). 13C NMR 
(150 MHz, CD3OD): δ 180.7, 176.8, 53.0, 48.3, 48.2, 47.5, 46.2, 45.9, 40.2, 37.8, 36.7, 35.5, 
34.8, 33.3, 33.1, 32.3, 29.3, 29.1, 27.8 (2C), 27.6, 27.5, 27.4, 27.2, 25.4, 24.3 (2C). 
PhTX analogue 14 (14): Yield: 56 mg (45%); tR = 19.17 min. HRMS: calcd for C28H54N5O2 
[M + H]+ 492.4273, found 492.4271. 1H NMR (600 MHz, CD3OD): δ 4.26 (1H, dd, J = 8.9 
and 5.5 Hz, H-), 3.34 and 3.29 (each 1H, m, H-1), 3.13 (2H, br t, J = 7.8 Hz, -CH2-NH-), 
3.10-2.99 (8H, br m, 4 × -CH2-NH-), 2.25-1.95 (6H, H-2', H-9 and 2 × Norbornyl-H), 1.91-
1.66 (12H, H-2, H-5, H-6, 5 × cHex-Heq, Norbornyl-H), 1.62-1.36 (7H, H-β, H-, 4 × 
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Norbornyl-H), 1.35-1.08 (7H, 4 × Norbornyl-H, 3 × cHex-Hax ), 1.02-0.87 (2H, br m, cHex-
Hax). 
13C NMR (150 MHz, CD3OD): δ 176.6*, 175.9*, 53.0*, 48.3, 48.2, 46.2, 45.9, 43.7*, 
42.3**, 42.2**, 40.7**, 40.5**, 40.1**, 40.0**, 38.6, 38.0*, 37.8, 36.7, 36.0**, 35.9**, 35.5**, 35.4**, 
34.9, 33.1*, 30.9**, 30.8**, 29.6*, 27.6**, 27.5**, 27.4*, 27.2, 25.4, 24.3 (2C); * two close peaks 
arising from two rotamers or the presence of an additional chiral center; **peak splitting due to 
presence of two rotamers the presence of an additional chiral center.    
PhTX analogue 15 (15): Yield: 55 mg (46%); tR = 17.11 min. HRMS: calcd for C26H46N5O2 
[M + H]+ 460.3646, found 460.3645. 1H NMR (600 MHz, CD3OD): δ 7.88 (2H, br d, J = 8.5 
Hz, H-2' and H-6'), 7.57 (1H, br t, J = 8.5 Hz, H-4'), 7.49 (2H, br t, J = 7.7 Hz, H-3' and H-5'), 
4.48 (1H, dd, J = 10.0  and 5.3 Hz, H-), 3.42 and 3.29 (each 1H, m, H-1), 3.11-2.98 (10H, br 
m, H-3, H-4, H-7, H-8 and H-10), 2.07 (2H, br p, J = 7.5 Hz, H-9), 1.90 (1H, m, H-2), 1.85-
1.72 (9H, br m, H-5, H-6, 4 × cHex-Heq and HA-β), 1.70-1.65 (2H, br m, HB-β and cHex-Heq), 
1.34-1.17 (3H, br m, cHex-Hax), 1.06-0.94 (2H, br m, cHex-Hax). 
13C NMR (150 MHz, 
CD3OD): δ 176.8, 170.7, 135.1, 133.1, 129.6 (2C), 128.6 (2C), 54.0, 48.2, 48.1, 46.1, 45.9, 
40.0, 37.8, 36.7, 35.7, 34.8, 33.5, 27.6, 27.5, 27.4, 27.2, 25.4, 24.2 (2C).   
PhTX anlalogue 16 (16): Yield: 54 mg (42%); tR = 20.60 min. HRMS: calcd for C31H50N5O2 
[M + H]+ 524.3965, found 524.3957. 1H NMR (600 MHz, CD3OD): δ 8.08 (1H, br d, J = 7.6 
Hz, Ar-H), 7.90 (1H, br d, J = 7.6 Hz, Ar-H), 7.83 (1H, m, Ar-H), 7.56-7.50 (2H, br m, Ar-H), 
7.47-7.45 (2H, br m, Ar-H), 4.24 (1H, dd, J = 10.5 and 5.5 Hz, H-), 4.10 and 4.06 (each 1H, 
d, J = 15.5 Hz, H-2'), 3.35 and 3.23 (each 1H, m, H-1), 3.10-2.98 (4H, m, H-8 and H-10), 2.97 
(2H, m, H-4/H-7), 2.83 (2H, t, J = 7.2 Hz, H-3), 2.74 (2H, m, H-4/H-7), 2.06 (2H, br p, J = 7.7 
Hz, H-9), 1.80 (2H, br p, J = 6.7 Hz, H-2), 1.72-1.53 (11H, br m, H-5, H-6, H-β, cHex-Heq), 
1.27 (1H, m, H-), 1.24-1.03 (3H, br m, cHex-Hax), 0.97-0.81 (2H, br m, cHex-Hax). 13C NMR 
(150 MHz, CD3OD): δ 176.4, 174.4, 135.4, 133.6, 133.1, 129.8, 129.2, 129.0, 127.4, 126.9, 
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126.7, 125.1, 53.5, 48.2, 47.9, 46.0, 45.8, 41.0, 40.0, 37.8, 36.7, 35.3, 34.9, 33.2, 27.5 (2C), 
27.3, 27.1, 25.4, 24.2, 24.1.  
PhTX analogue 17 (17): Yield: 51 mg (41%); tR = 20.01 min. HRMS: calcd for C28H48N5O2 
[M + H]+ 486.3803, found 486.3802. 1H NMR (600 MHz, CD3OD): δ 7.58 (2H, dd, J = 8.0 
and 1.4 Hz, H-2' and H-6'), 7.55 (1H, d, J = 15.8 Hz, H-β'), 7.43-7.38 (3H, br m, H-3', H-4', H-
5'), 6.74 (1H, d, J = 15.8 Hz, H-'), 4.38 (1H, dd, J = 9.1 and 6.0 Hz, H-), 3.39 and 3.29 (each 
1H, m, H-1), 3.09-3.00 (10H, H-3, H-4, H-7, H-8 and H-10), 2.05 (2H, m, H-9), 1.90 (2H, m, 
H-2), 1.83-1.71 (8H, br m, H-5, H-6 and 4 × cHex-Heq), 1.70-1.60 (3H, br m, cHex-Heq and H-
β), 1.43 (1H, m, H-), 1.34-1.16 (3H, m, cHex-Hax), 1.05-0.92 (2H, br m, cHex-Hax). 13C NMR 
(150 MHz, CD3OD): δ 176.7, 168.8, 142.3, 136.1, 131.1, 130.1 (2C), 128.9 (2C), 121.4, 53.5, 
48.3, 48.1, 46.1, 45.9, 40.3, 37.8, 36.7, 35.5, 34.9, 33.4, 27.6, 27.5, 27.4, 27.2, 25.4, 24.3 (2C).  
Preparation of Xenopus oocytes and injection of cRNA. Oocytes isolated from mature 
female Xenopus laevis were supplied by the European Xenopus Resource Centre, University 
of Portsmouth, UK. Oocytes were treated with collagenase (0.5 mg/mL, Sigma type 1A) in 
Ca2+-free solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM HEPES, 2.5 mM sodium 
pyruvate, 100 U/mL penicillin, 0.1 mg/mL streptomycin, pH 7.5) with shaking at 19°C to 
separate individual oocytes from the connective tissue and to remove the follicular layer 
surrounding the cells. After separation, oocytes were washed 7 times with modified Barth’s 
solution (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, 2.5 mM 
sodium pyruvate, 0.5 mM theophylline, 50 μg/mL gentamicin, pH 7.5) and kept at 19°C in the 
same solution. 
Healthy oocytes were injected with cRNA by using a Nanoliter Injector (World Precision 
Instruments, USA). Mixtures of nAChR subunit cRNAs were injected with a 1:1 ratio of α:β 
subunit at 200 ng/µL. Each oocyte was injected with 50 nL of RNA solution. Injected oocytes 
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were kept in Barth’s solution at 19°C for two or three days to allow for expression of nAChRs. 
During this time oocytes were regularly inspected to remove unhealthy ones. 
Electrophysiology. Electrophysiological recordings were obtained from nAChR-
expressing oocytes by the two-electrode voltage clamp (TEVC) method, using a Geneclamp 
500 voltage clamp amplifier (Axon instruments, USA). Oocytes were placed in a perfusion 
chamber by using a plastic Pasteur pipette and perfused (~5 mL/min) with fresh Frog Ringer 
solution (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2 and 5 mM HEPES, pH 7.5). Microelectrodes 
were pulled from borosilicate glass capillaries (Harvard GC150TF-10) using a programmable 
micropipette puller (Sutter P97, USA), such that they had a resistance of between 0.5 and 2.5 
MΩ when filled with 3 M KCl. Oocytes were voltage-clamped at a holding potential (VH) of 
100 mV. ACh was consistently used as the agonist, and it was applied at a fixed concentration 
without or together with variable concentrations of each of the PhTX analogues using an 8-
channel perfusion system (Automate, USA) for 1 min to allow for equilibration of the current. 
Output from the amplifier was transferred to a PC via a digidata 1200 digital interface (Axon 
Instuments, USA) by using WinEDR v3.2.6 Software (Dr John Dempster, University of 
Strathclyde, UK).  
Data analysis. WinEDR was used to measure the current amplitude of responses to 
ACh at the end of the one-minute application (i.e., “late” current) in order to allow for 
equilibration of the inhibitory effect, and hence to achieve improved comparison of the effect 
of test compounds. Currents in the presence of each concentration of each PhTX analogue were 
normalised as percentage of the control response (i.e., to ACh alone), and subsequently these 
were plotted against PhTX concentration. Graphpad Prism 7 was used for data analysis, graph 
plotting, and curve fitting. All plotted data points are the mean ± SEM, obtained from analysis 
of 4-20 oocytes. Concentration-inhibition curves were used to estimate IC50 values by using 
the following equation (where nH is the Hill slope): 
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𝑃𝑒𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒 =  
100%
1 + 10(𝐿𝑜𝑔[𝑃ℎ𝑇𝑋]−𝐿𝑜𝑔𝐼𝐶50)𝑛𝐻
                    (Eq. 1) 
IC50 values were compared for significant differences by using an extra sum of squares F-test 
in Graphpad Prism 7. 
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Abbreviations: ACh, acetylcholine; AMPA, α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid; Boc; tert-butyloxycarbonyl; cBu, cyclobutyl; Cha, cyclohexylalanine; 
cHep, cycloheptyl;  cHex, cyclohexyl; cPent, cyclopentyl; DIC, diisopropylcarbodiimide; 
Fmoc, fluoren-9-yl-methyloxycarbonyl; HOBt, 1-hydroxybenzotriazol; IC50, concentration 
that results in 50% inhibition of the maximal response; iGluR, ionotropic glutamate receptor; 
nAChR, nicotinic acetylcholine receptor; NMDA, N-methyl-D-aspartate; PhTX, 
philanthotoxin; SPS, solid-phase synthesis; Teoc, 2-(trimethylsilyl)ethyloxycarbonyl; TEVC, 
two-electrode voltage clamp. 
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